Palvella Therapeutics (NASDAQ:PVLA) Upgraded at Chardan Capital

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by equities research analysts at Chardan Capital to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other research analysts also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Stephens reiterated an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $199.53.

Palvella Therapeutics Trading Up 5.3%

Shares of NASDAQ PVLA opened at $150.19 on Tuesday. The stock has a fifty day moving average price of $129.69 and a 200 day moving average price of $118.14. Palvella Therapeutics has a 12-month low of $34.57 and a 12-month high of $161.38. The company has a market cap of $2.15 billion, a P/E ratio of -36.02 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, sell-side analysts forecast that Palvella Therapeutics will post -5.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV bought a new position in Palvella Therapeutics during the first quarter worth $28,000. Group One Trading LLC lifted its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth approximately $167,000. Finally, Keybank National Association OH bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth approximately $228,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.